Brief: IRLAB Sees Positive Data From First Part Of Phase I Study With Drug Candidate IRL757
03/10/2024 06:12
Oct 3 (Reuters) - IRLAB Therapeutics AB IRLABa.ST :
* POSITIVE DATA FROM THE FIRST PART OF IRLAB'S PHASE I STUDY
WITH
THE DRUG CANDIDATE IRL757
* RESULTS SHOW THAT IRL757 IS WELL ABSORBED, PROVIDES GOOD
EXPOSURE IN BODY AND HAS A GOOD TOLERABILITY
Source text for Eikon: ID:nMFN397P4y
Further company coverage: IRLABa.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))